4 recruiting, 3 unknown, 1 active not recruiting, 1 completed. 4 Phase 2, 3 Phase 3, 2 Not applicable, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Unknown 1 |
| Phase 3 | 3 | Unknown 2, Completed 1 |
| Not applicable | 2 | Recruiting 2 |
| Phase 1 | 2 | Recruiting 1, Unknown 1 |
Follow High Risk Acute Myeloid Leukemia: new trials by email Literature Review of High Risk Acute Myeloid Leukemia trials Research Report on High Risk Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3 - Leukemia, High Risk Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 100 | 2025-03-21 | 2026-04-15 |
| Novel Digital Application for Patients With Acute Leukemia DREAMLAND, VITAL WELLNESS - Relapsed Adult Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia | Not applicable | Recruiting | Massachusetts General Hospital | 200 | 2024-10-21 | 2025-11-10 |
| Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients venetoclax, azacitidine and HAAG regimen - Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 60 | 2024-02-15 | 2024-05-01 |
| Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia Specialty Palliative Care, Primary Palliative Care - Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia | Not applicable | Recruiting | Massachusetts General Hospital | 2300 | 2022-06-01 | 2025-07-25 |
| Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT boost anti-viral immunity after T-cell depleted HSCT - Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 20 | 2021-09-16 | 2021-10-04 |
| Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 204 | 2016-08-05 | 2026-08-06 |
| CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML Cladribine, Fludarabine, Busulfan - High Risk Acute Myeloid Leukemia, Allogeneic Hematopoeitic Stem Cell Transplantation | Phase 3 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 120 | 2016-08-01 | 2021-10-12 |
| CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML Cladribine, Fludarabine, Busulfan - High Risk Acute Myeloid Leukemia, Allogeneic Hematopoeitic Stem Cell Transplantation | Phase 3 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 120 | 2016-08-01 | 2021-10-12 |
| Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia CPX-351, 7+3 (cytarabine and daunorubicin) - High Risk Acute Myeloid Leukemia | Phase 3 | Completed | Jazz Pharmaceuticals | 309 | 2012-12-13 | 2020-08-10 |
Leukemia, Myeloid, Acute (5) · Lymphoma, Non-Hodgkin (3) · Myelodysplastic Syndromes (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Anemia, Refractory, with Excess of Blasts (1) · Bone Marrow Failure Disorders (1) · Congenital Bone Marrow Failure Syndromes (1) · Hematologic Neoplasms (1) · Hemoglobinopathies (1) · Hodgkin Disease (1) · Immunologic Deficiency Syndromes (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoproliferative Disorders (1)
Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Leukemia (5) · Leukemia, Myeloid (5) · Bone Marrow Diseases (3) · Disease Attributes (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Leukemia, Lymphoid (2)
Busulfan (3) · Cytarabine (3) · fludarabine (3) · Cladribine (2) · Azacitidine (1) · CPX-351 (1) · Clinical Trials, Phase I as Topic (1) · Cyclophosphamide (1) · Daunorubicin (1) · Mycophenolic Acid (1) · Tacrolimus (1) · Thiotepa (1) · fludarabine phosphate (1) · venetoclax (1)
Massachusetts General Hospital (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Children's Hospital of Philadelphia (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Jazz Pharmaceuticals (1) · M.D. Anderson Cancer Center (1) · The First Affiliated Hospital of Soochow University (1)
United States (5) · China (3) · Canada (1) · Russia (1)
Chun Wang, M.D.,Ph. D. (2) · Areej El-Jawahri, MD (1) · Jennifer Temel, MD (1) · Timothy Olson, MD, PhD (1) · Uday R Popat, MD (1) · Xiaowen Tang, Ph.D (1)
PMID 26660428, PMID 30024784, PMID 31760835, PMID 33724305, PMID 34171279, PMID 34256819, PMID 36289532, PMID 37611156, PMID 40990091, PMID 41628350
R01CA288550 (1)